Search
Upadacitinib
go.drugbank.com/drugs/DB15091ApprovedInvestigational[A189165] Despite a variety of therapeutic agents available for treatment, up to 40% of the patients do not respond to current therapies, including biological therapies. … Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints.
SYNB1020
go.drugbank.com/drugs/DB17667Investigationaldiscontinued further development of SYNB1020 to treat hyperammonemia due to a lack of evidence of ammonia-lowering activities by SYNB1020 in a Phase 1b/2a study. … It was initially designed to convert ammonia to L-arginine [A258838] and granted orphan designation by the FDA for the treatment of urea cycle disorders in August 2016;[L45988] however, the manufacturer
Gold
go.drugbank.com/drugs/DB14154InvestigationalA yellow metallic element with the atomic symbol Au, atomic number 79, and atomic weight 197. It is used in jewelry, goldplating of other metals, as currency, and in dental restoration.
RUS 3108
go.drugbank.com/drugs/DB05911ExperimentalRUS 3108 is being developed for the treatment of atherosclerosis, the major cause of cardiovascular disorders such as heart attacks and stroke by Dr. Reddy’s Laboratories.
Lifitegrast
go.drugbank.com/drugs/DB11611ApprovedInvestigationalIt is a tetrahydroisoquinoline derivative and lymphocyte function-associated antigen-1 ( LFA-1) antagonist that was discovered through the rational design process. … Lifitegrast is a FDA approved drug for the treatment of keratoconjunctivitis sicca (dry eye syndrome).
Categories: Compounds used in a research, industrial, or household settingQRX-411
go.drugbank.com/drugs/DB17868ExperimentalIt addresses the underlying cause of Usher syndrome due to the c.7595-2144A>G mutation in the _USH2A_ gene.[L46777] … QRX-411 is a first-in-class RNA-based oligonucleotide designed to restore wild-type USH2A mRNA, leading to the production of the functional USH2A protein.
Ouabain
go.drugbank.com/drugs/DB01092ApprovedIt is commonly used in cell biological studies as an inhibitor of the NA(+)-K(+)-exchanging ATPase. … A cardioactive glycoside consisting of rhamnose and ouabagenin, obtained from the seeds of Strophanthus gratus and other plants of the Apocynaceae; used like digitalis.
Categories: Compounds used in a research, industrial, or household settingSynonyms: Ouabagenin-L-rhamnosid, Ouabagenin L-RhamnosidePegunigalsidase alfa
go.drugbank.com/drugs/DB14992ApprovedInvestigational[A259347,A259352] In May 2023, the EMA granted marketing authorization to pegunigalsidase alfa in the European Union (EU) for the treatment of adult patients with Fabry disease. … Pegunigalsidase alfa (PRX-102) is a recombinant form of human α-galactosidase-A indicated for long-term enzyme replacement therapy in patients with Fabry disease, a rare genetic disorder characterized
MBO7133
go.drugbank.com/drugs/DB04999ExperimentalHigher doses of araC cannot be used to overcome this limitation due to bone marrow toxicity resulting from rapid activation in that tissue. … MB07133 uses our HepDirect technology to target a prodrug form of araCMP specifically to the liver.
Vilazodone
go.drugbank.com/drugs/DB06684ApprovedInvestigationalVilazodone is a novel compound with combined high affinity and selectivity for the 5-hydroxytryptamine (5-HT) transporter and 5-HT(1A) receptors[Label,A177622].